News und Analysen
2 Monster Stocks to Buy Without Any Hesitation
Investing in stocks is a great way for most people to grow their wealth over time. However, all stocks aren't created equal. Some are unlikely to deliver anything resembling solid returns over the
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer plans to amend its dividend policy to reduce debt
EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
January was a big month for pharmaceutical stocks, with Merck (NYSE: MRK), Eli Lilly (NYSE: LLY), and Novo Nordisk (NYSE: NVO) all climbing 11%, according to data provided by S&P Global Market
Why Merck Stock Rocketed Nearly 5% Skyward Today
Veteran healthcare company Merck (NYSE: MRK) was looking very healthy on the stock market Thursday. Its shares gained 4.6% in value across the day, following the publication of quarterly results
Merck (MRK) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Merck (NYSE: MRK)Q4 2023 Earnings CallFeb 01, 2024, 9:00 a.m. ET
Operator
Source Fool.com
EQS-Adhoc: Carl Zeiss Meditec AG agrees to launch share buyback program with volume of up to €150m
A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years
With the S&P 500 index recently hitting a new all-time high, we can officially declare that we are in a bull market. While that's exciting news, it doesn't change the blueprint of success for
This 1 Bullish Move by Merck Could Drive Growth for Years to Come
On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics, (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the
EQS-News: U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS
EQS-News: Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)
EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.
EQS-News: Carl Zeiss Meditec increased revenue in fiscal year 2022/23 by around 10 percent
5 Dividend Stocks That Recently Increased Their Payouts
My favorite stocks to invest in are those that continuously increase their dividend. Merck & Co (NYSE: MRK) is one stock that I like a lot that has been growing its dividend at a solid clip for a
EQS-Adhoc: Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA: Favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million – 2023 earnings outlook raised
Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?
A dividend yield can tell you a lot about a payout. Not only does it tell you how much you could be collecting in dividend income, but it can give you an indication of investor sentiment, and
EQS-Adhoc: Bayer Aktiengesellschaft: OCEANIC-AF study stopped early due to lack of efficacy
2 Healthcare Stocks That Could Make You Richer
As far as healthcare stocks go, drugmaker Merck (NYSE: MRK) and medical device expert Intuitive Surgical (NASDAQ: ISRG) haven't been the best of the bunch this year. Both are lagging the market in
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
Merck (NYSE: MRK) and Bristol Myers Squibb (NYSE: BMY) are both eyeing the same pie, and they're both serious about getting a big slice. But it isn't a hot market for drugs to treat a single disease
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care AG & Co. KGaA raises outlook for operating income in fiscal year 2023
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a
Merck (MRK) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Merck (NYSE: MRK)Q3 2023 Earnings CallOct 26, 2023, 9:00 a.m. ET
Operator
Source Fool.com
3 Safe Dividend Stocks to Beat Inflation
Like it or not, inflation remains higher than Americans have been accustomed to, and the impacts of last year's price surge have not gone away. As of September, inflation as measured by the Consumer